RDS welcomes MACSF as investor to help drive transformation of patient pathway

• Insurer’s contribution supplements existing €13 million seed funding raised since inception          

• Start-up confirms goal to bring MultiSense^® solution to market in early 2024     

• MACSF commits to series A funding for RDS, planned for 2024

Strasbourg, France, January 17, 2024 – RDS, the medical device start-up responsible for developing MultiSense^®, its patented connected solution for Remote Patient Monitoring (RPM), today welcomes MACSF (Mutuelle d’Assurance du Corps de Santé Français) to its investor pool. MACSF invested €1 million ($1.1M), taking the total funding raised since the inception of the start-up in 2020 to €14 million ($15.3M). The insurer is also undertaking to contribute to RDS’ series A funding round, planned for 2024.

This funding will enable RDS to progress with the anticipated commercial launch of MultiSense in early 2024. The series A fundraising planned for later this year will facilitate the marketing of MultiSense in Europe, the continued development of the company’s products, the launch of new clinical trials and product registration with the US authorities, ready for its release there in 2025.

“Welcoming MACSF – France’s leading provider of insurance solutions for health care professionals – on board as an investor is of course highly symbolic for RDS,” said Elie Lobel, CEO of RDS. “Beyond the improvement in patient care, our rollout of the MultiSense solution also has tangible positive impacts in terms of CSR and sustainability, in full alignment with MACSF’s investment policy.”

“MACSF is delighted to be joining forces with RDS in its novel approach, designed to improve quality of care, enhance patient safety and optimize clinical time. This investment reflects our commitment to transforming medical practices to provide increasingly effective care to meet each individual’s needs,” added Dr. Thierry Houselstein, MACSF’s medical director.

MultiSense is a class IIa medical device providing health care professionals with a high precision, comprehensive, multi-parameter solution for continuous monitoring of patients’ health in hospital or at home. The solution connects a wearable patch with a cloud-based platform and associated support services. The first version provides continuous measurement of six key parameters: heart rate, respiratory rate, oxygen saturation, skin temperature, patients’ level of activity and their posture. The product is protected by more than 20 patents. Sustainable development has been key from the start: the device can be cleaned, refurbished and reused, to minimize its carbon footprint. MultiSense is intended to make it easier to introduce short stay hospitalization protocols to reduce the average length of hospital stays, make hospital discharge safer and improve patients’ quality of life.

The global remote patient monitoring market was valued at around $53.6 billion (€49bn) in 2022, with average annual growth of 26.7% forecast for the period 2022 to 2027. The backdrop to RDS’ operations within this market is extremely positive, driven by the widespread adoption of short stay hospitalization protocols, the gradual increase in eligibility for reimbursement of Remote Patient Monitoring (RPM) solutions and the significant pressure on hospital resources.

About MACSF Group

France’s leading insurer for health care professionals, MACSF (Mutuelle d’assurance du corps de santé français) has over 100 years’ experience of providing services to all those employed in health care occupations. It employs 1,600 people and generates revenues in the region of €3 billion ($3.3bn). In keeping with its mission as a professional mutual insurer, MACSF provides cover for personal and occupational risks for over one million members and customers.

www.macsf.fr

About RDS 

RDS develops MultiSense^®, a next-generation Remote Patient Monitoring (RPM) solution comprising a wearable patch monitor for collecting high-quality, real-time physiological data, in hospital or at home, and a cloud-based platform for healthcare professionals to transform these data into actionable insights. MultiSense is protected by more than 20 patents and has been validated in six clinical trials. Marketing in Europe is expected to begin in early 2024.

RDS relies on its talented international team and has received numerous accolades, including the i-Lab prize in 2020, the Grand Prix de l’Académie des Technologies in 2022 and the i-Nov award in 2023.

The company was founded in 2020 and is based in Strasbourg, France. It is incubated at SEMIA/Quest for Health and is part of the Future4Care accelerator program. It currently employs around 20 staff.

www.rdsdiag.com